Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in…
Protagonist Therapeutics, Inc. announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration agreement with Janssen Biotech, Inc., have been…
Read More...
Read More...
